Retrieval of the RNA-seq data at the EMBL-EBI expression atlas (www.ebi.ac.uk/gxa/home), last accessed May 2019) uncovered 26 experiments for Insl5 and 25 for Rxfp4 in which significant differences were observed between treatment arms: five of these studies found decreased expression of Insl5 or Rxfp4 in association with metabolic disorders such as Crohn’s disease, while 22 (11-Insl5, 11-Rxfp4) found significant changes in gene expression associated with various cancer including colon and breast (summarized in Table S3). Here, RXFP4 is linked to cancer.